Opinion

Video

Population Outcomes and Return on Value With CGMs

Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.

Video content above is prompted by the following:

  1. What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
  2. Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
5 experts are featured in this series
5 experts are featured in this series
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo